Cargando…

Introduction of sacubitril/valsartan in primary care follow‐up of heart failure: a prospective observational study (THESEUS)

AIMS: Switch from angiotensin converting enzyme inhibitor treatment to sacubitril/valsartan (sac/val) is associated with benefit in heart failure with reduced ejection fraction (HFrEF). Reports on management of this switch are largely based on randomized controlled trials, retrospective analyses, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Dieterle, Thomas, Schaefer, Stefan, Meyer, Ina, Ackermann, Gabriele, Ahmed, Kashan, Hullin, Roger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373939/
https://www.ncbi.nlm.nih.gov/pubmed/32369265
http://dx.doi.org/10.1002/ehf2.12716
_version_ 1783561593482641408
author Dieterle, Thomas
Schaefer, Stefan
Meyer, Ina
Ackermann, Gabriele
Ahmed, Kashan
Hullin, Roger
author_facet Dieterle, Thomas
Schaefer, Stefan
Meyer, Ina
Ackermann, Gabriele
Ahmed, Kashan
Hullin, Roger
author_sort Dieterle, Thomas
collection PubMed
description AIMS: Switch from angiotensin converting enzyme inhibitor treatment to sacubitril/valsartan (sac/val) is associated with benefit in heart failure with reduced ejection fraction (HFrEF). Reports on management of this switch are largely based on randomized controlled trials, retrospective analyses, and hospital‐based care, while patients with chronic heart failure (CHF) are frequently followed‐up in primary care. The THESEUS study aimed to characterize the transition to sac/val and early maintenance period of HFrEF in primary care. METHOD AND RESULTS: THESEUS was a prospective, observational, non‐interventional study, performed at primary care sites throughout Switzerland. Patient characteristics, sac/val transition, and maintenance were reported at study enrolment and approximately 3 and 6 months after sac/val initiation. The primary endpoint was achievement of 200 mg BID sac/val with maintenance for ≥12 weeks. Secondary outcomes included dosing regimens, healthcare utilization in the 6 months prior to sac/val initiation and during the study, patient well‐being, safety, and tolerability. Fifty‐eight patients with CHF were enrolled from 45 primary care centres. Six patients were excluded, and 19 achieved the primary endpoint (36.5%, Achievers). Non‐Achievers underwent fewer titration steps than Achievers (1.9 ± 0.9 vs. 3.1 ± 1.4). In both groups, patient well‐being improved and the percentage of New York Heart Association III patients decreased. Healthcare utilization decreased (19% vs. 30.8% in the 6 months pre‐enrolment period). The most frequent reasons for target dose non‐achievement were asymptomatic and symptomatic hypotension (15.3% and 12.1%, respectively). CONCLUSIONS: Results from THESEUS suggest that transition to sac/val is manageable in primary care, with a safety profile corresponding to reports from specialized heart failure care.
format Online
Article
Text
id pubmed-7373939
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-73739392020-07-22 Introduction of sacubitril/valsartan in primary care follow‐up of heart failure: a prospective observational study (THESEUS) Dieterle, Thomas Schaefer, Stefan Meyer, Ina Ackermann, Gabriele Ahmed, Kashan Hullin, Roger ESC Heart Fail Original Research Articles AIMS: Switch from angiotensin converting enzyme inhibitor treatment to sacubitril/valsartan (sac/val) is associated with benefit in heart failure with reduced ejection fraction (HFrEF). Reports on management of this switch are largely based on randomized controlled trials, retrospective analyses, and hospital‐based care, while patients with chronic heart failure (CHF) are frequently followed‐up in primary care. The THESEUS study aimed to characterize the transition to sac/val and early maintenance period of HFrEF in primary care. METHOD AND RESULTS: THESEUS was a prospective, observational, non‐interventional study, performed at primary care sites throughout Switzerland. Patient characteristics, sac/val transition, and maintenance were reported at study enrolment and approximately 3 and 6 months after sac/val initiation. The primary endpoint was achievement of 200 mg BID sac/val with maintenance for ≥12 weeks. Secondary outcomes included dosing regimens, healthcare utilization in the 6 months prior to sac/val initiation and during the study, patient well‐being, safety, and tolerability. Fifty‐eight patients with CHF were enrolled from 45 primary care centres. Six patients were excluded, and 19 achieved the primary endpoint (36.5%, Achievers). Non‐Achievers underwent fewer titration steps than Achievers (1.9 ± 0.9 vs. 3.1 ± 1.4). In both groups, patient well‐being improved and the percentage of New York Heart Association III patients decreased. Healthcare utilization decreased (19% vs. 30.8% in the 6 months pre‐enrolment period). The most frequent reasons for target dose non‐achievement were asymptomatic and symptomatic hypotension (15.3% and 12.1%, respectively). CONCLUSIONS: Results from THESEUS suggest that transition to sac/val is manageable in primary care, with a safety profile corresponding to reports from specialized heart failure care. John Wiley and Sons Inc. 2020-05-05 /pmc/articles/PMC7373939/ /pubmed/32369265 http://dx.doi.org/10.1002/ehf2.12716 Text en © 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research Articles
Dieterle, Thomas
Schaefer, Stefan
Meyer, Ina
Ackermann, Gabriele
Ahmed, Kashan
Hullin, Roger
Introduction of sacubitril/valsartan in primary care follow‐up of heart failure: a prospective observational study (THESEUS)
title Introduction of sacubitril/valsartan in primary care follow‐up of heart failure: a prospective observational study (THESEUS)
title_full Introduction of sacubitril/valsartan in primary care follow‐up of heart failure: a prospective observational study (THESEUS)
title_fullStr Introduction of sacubitril/valsartan in primary care follow‐up of heart failure: a prospective observational study (THESEUS)
title_full_unstemmed Introduction of sacubitril/valsartan in primary care follow‐up of heart failure: a prospective observational study (THESEUS)
title_short Introduction of sacubitril/valsartan in primary care follow‐up of heart failure: a prospective observational study (THESEUS)
title_sort introduction of sacubitril/valsartan in primary care follow‐up of heart failure: a prospective observational study (theseus)
topic Original Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373939/
https://www.ncbi.nlm.nih.gov/pubmed/32369265
http://dx.doi.org/10.1002/ehf2.12716
work_keys_str_mv AT dieterlethomas introductionofsacubitrilvalsartaninprimarycarefollowupofheartfailureaprospectiveobservationalstudytheseus
AT schaeferstefan introductionofsacubitrilvalsartaninprimarycarefollowupofheartfailureaprospectiveobservationalstudytheseus
AT meyerina introductionofsacubitrilvalsartaninprimarycarefollowupofheartfailureaprospectiveobservationalstudytheseus
AT ackermanngabriele introductionofsacubitrilvalsartaninprimarycarefollowupofheartfailureaprospectiveobservationalstudytheseus
AT ahmedkashan introductionofsacubitrilvalsartaninprimarycarefollowupofheartfailureaprospectiveobservationalstudytheseus
AT hullinroger introductionofsacubitrilvalsartaninprimarycarefollowupofheartfailureaprospectiveobservationalstudytheseus